Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Trimbow

    - PMLiVE

    GSK and Hengrui enter multi-programme collaboration agreement worth $12bn

    The deal includes a PDE3/4 inhibitor in clinical development for COPD

    - PMLiVE

    Merck to expand respiratory disease portfolio with $10bn Verona acquisition

    The deal includes a drug approved in the US for chronic obstructive pulmonary disease

    - PMLiVE

    UK researchers uncover first new asthma and COPD attack treatment in 50 years

    The phase 2 study showed that benralizumab could be re-purposed for use in emergency settings

    - PMLiVE

    Chiesi and Oak Hill enrol first European patient in phase 2b premature birth study

    The trial is evaluating OHB-607 for preventing bronchopulmonary dysplasia and other complications

    - PMLiVE

    Chiesi Group invests €400m to establish biotech centre of excellence in Italy

    The facility is dedicated to developing and producing monoclonal antibodies, enzymes and other proteins

    - PMLiVE

    Sanofi/Regeneron’s Dupixent approved by MHRA to treat uncontrolled COPD

    Approximately 1.4 million people in the UK have been diagnosed with the respiratory disease

    - PMLiVE

    GSK announces positive late-stage results for IL-5 inhibitor Nucala in COPD

    The chronic respiratory disease affects more than 300 million people globally

    - PMLiVE

    Sanofi/Regeneron’s Dupixent approved by EMA for uncontrolled COPD in adults

    Approximately 220,000 COPD patients in the EU could be eligible for Dupixent treatment

    - PMLiVE

    New syndicated COPD report now available

    Living with COPD 2023

    Inizio

    - PMLiVE

    Sanofi/Regeneron’s Dupixent shows promise in chronic obstructive pulmonary disease

    Approximately 300,000 people in the US live with uncontrolled COPD with evidence of type 2 inflammation

    Covid-19: how is it affecting prescribing patterns?

    Oli Hudson, Content Director at Wilmington Healthcare, analyses prescribing data in three key disease areas

    Wilmington Healthcare

    AstraZeneca AZ

    AZ builds case for its COPD triple as it chases GSK’s Trelegy

    Awaiting approvals in Europe and the US

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links